Over time, extensive R&D on the potentialhealth benefits of cannabis, have enabled medical researchers to identify anumber of pharmacologically active ingredients that offer clinical benefit,minus the addictive properties of the crude substance. Currently, severalstakeholders in the pharmaceutical industry are actively engaged in the effortsto develop leads based on natural and synthetic derivatives of cannabinoids.
To order this 250+ page report, which features140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
The over USD 5 billion (by 2030)financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across thefollowing segments:
§ Target DiseaseIndication
§ Cancer
§ Genetic Disorders
§ NeurologicalIndications
§ Others
§ Route of Administration
§ Oral
§ Inhalation
§ Key Geographies
§ North America
§ Europe
Asia-Pacificand the Rest of the World
The“EndocannabinoidSystem Targeted Therapeutics Market, 2020-2030" report features the followingcompanies, which we identified to be key players in this domain:
§ GW Pharmaceuticals
§ Corbus Pharmaceuticals
§ Tilray
§ Tetra Bio-Pharma
§ Botanix Pharmaceuticals
§ Kalytera Therapeutics
§ Therapix Biosciences
§ Echo Pharmaceuticals
§ Avicanna
§ GB Sciences
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET LANDSCAPE:ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS
5. COMPANY PROFILES
6. ACADEMIC GRANTS ANALYSIS
7. PARTNERSHIPS ANDCOLLABORATIONS
8. MERGERS AND ACQUISITIONS
9. DRUG DEVELOPMENTSTRATEGY ANALYSIS
10. MARKET FORECAST ANDOPPORTUNITY ANALYSIS
11. CONCLUDING REMARKS
12. EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATEDDATA
14. APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS
To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
